PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

NCT05501340 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Malignant Ascites

Interventions

DRUG: Serplulimab
DRUG: Molgramostim
RADIATION: Hypofractionated radiotherapy/Sterotactic body radiotherapy

Sponsor

Second Affiliated Hospital of Soochow University